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Abstract
Introduction: Etomidate is no longer administered as a continuous infusion for anesthetic maintenance or
sedation, because it results in profound and persistent suppression of adrenocortical steroid synthesis with
potentially lethal consequences in critically ill patients. We hypothesized that rapidly metabolized soft analogues
of etomidate could be developed that do not produce persistent adrenocortical dysfunction even after
prolonged continuous infusion. We hope that such agents might also provide more rapid and predictable
anesthetic emergence. We have developed the soft etomidate analogue cyclopropyl-methoxycarbonyl
etomidate (CPMM). Upon termination of 120-minute continuous infusions, hypnotic and encephalographic
recoveries occur in four minutes. The aims of this study were to assess adrenocortical function during and
following 120-minute continuous infusion of CPMM and to compare the results with those obtained using
etomidate.
Methods: Dexamethasone-suppressed rats were randomized into an etomidate group, CPMM group, or control
group. Rats in the etomidate and CPMM groups received 120-minute continuous infusions of etomidate and
CPMM, respectively. Rats in the control group received neither hypnotic. In the first study, adrenocortical function
during hypnotic infusion was assessed by administering adrenocorticotropic hormone (ACTH) 90 minutes after the
start of the hypnotic infusion and measuring plasma corticosterone concentrations at the end of the infusion 30
minutes later. In the second study, adrenocortical recovery following hypnotic infusion was assessed by
administering ACTH every 30 minutes after infusion termination and measuring plasma corticosterone
concentrations 30 minutes after each ACTH dose.
Results: During hypnotic infusion, ACTH-stimulated serum corticosterone concentrations were significantly lower in
the CPMM and etomidate groups than in the control group (100 ± 64 ng/ml and 33 ± 32 ng/ml versus 615 ± 265
ng/ml, respectively). After hypnotic infusion, ACTH-stimulated serum corticosterone concentrations recovered to
control values within 30 minutes in the CPMM group but remained suppressed relative to those in the control
group for more than 3 hours in the etomidate group.
Conclusions: Both CPMM and etomidate suppress adrenocortical function during continuous infusion. However,
recovery occurs significantly more rapidly following infusion of CPMM.
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Introduction
Etomidate is an imidazole-based intravenous sedative-
hypnotic (Figure 1). It was developed by Janssen Phar-
maceuticals in the 1960s and introduced into clinical
practice as an anesthetic induction and maintenance
agent a decade later [1]. Since its introduction, wide-
spread concerns regarding its use, particularly in the cri-
tically ill, have arisen because it produces profound and
persistent adrenocortical suppression by inhibiting 11b-
hydroxylase [2-10].
Considering the hypothesis that rapidly metabolized
soft analogues of etomidate that would not produce per-
sistent adrenocortical suppression could be designed,
our laboratory developed methoxycarbonyl etomidate
[11]. Similar to remifentanil and esmolol, methoxycarbo-
nyl etomidate is rapidly metabolized by esterases to a
carboxylic acid metabolite. As a hypnotic and inhibitor
of adrenocortical steroid synthesis, this metabolite is
two to three orders of magnitude less potent than the
parent compound [12]. When given as an intravenous
bolus to rats, methoxycarbonyl etomidate is an extre-
mely short-acting hypnotic agent that maintains hemo-
dynamic stability and does not produce prolonged
adrenocortical suppression [11].
Subsequent continuous infusion studies demonstrated
that the very rapid metabolism of methoxycarbonyl
etomidate, along with its relatively low potency, necessi-
tated very high dosing to maintain hypnosis [13]. This
led to the accumulation of metabolite, and concentra-
tions in the blood and cerebrospinal fluid reached the
millimolar levels sufficient to produce pharmacological
effects that persisted for hours. We have now developed
a second-generation soft etomidate analogue, cyclopro-
pyl-methoxycarbonyl etomidate (CPMM), which is more
potent and longer-lasting than methoxycarbonyl etomi-
date but still more rapidly metabolized than etomidate
[14]. Unlike with methoxycarbonyl etomidate or etomi-
date, hypnotic and encephalographic recoveries occur in
4 minutes independently of infusion duration [15]. The
aims of this study were to assess adrenocortical function
during and after 120-minute continuous infusion of




All studies were conducted with the approval of the
Institutional Animal Care and Use Committee at Massa-
chusetts General Hospital (Boston, MA, USA) and in
accordance with its rules and regulations. Adult male
Sprague-Dawley rats (250 to 500 g) were purchased
from Charles River Laboratories (Wilmington, MA,
USA) and housed in the Massachusetts General Hospital
Center for Comparative Medicine animal care facility.
All intravenous drugs were administered through a
femoral venous catheter pre-implanted by the vendor
prior to animal delivery to our animal care facility. Each
rat was individually caged with controlled temperature
(21 ± 2°C) and light-dark cycles (7 a.m. to 7 p.m.) in the
Massachusetts General Hospital Center for Comparative
Medicine animal care facility, and food and water were
provided at libitum.
Drugs
Etomidate (2 mg/mL in 35% propylene glycol/water)
was from Hospira (Lake Forest, IL, USA). CPMM was
synthesized (> 97% purity) by Aberjona Laboratories
(Beverly, MA, USA) by using our previously described
approach [14] and solubilized at 5 mg/mL in 10% pro-
pylene glycol/normal saline. Dexamethasone was pur-
chased from American Regent (Shirley, NY, USA), and
adrenocorticotropic hormone (ACTH) was from Sigma-
Aldrich (St. Louis, MO, USA).
Hypnotic drug infusion protocol
Our goals were to achieve and maintain approximately
equivalent anesthetic depths during 120-minute hypnotic
infusions. Therefore, for each hypnotic, we used a continu-
ous infusion protocol that, as we previously determined
[15], achieves the following behavioral endpoints: (a) it
Figure 1 Chemical structures of etomidate, methoxycarbonyl
etomidate and cyclopropyl-methoxycarbonyl etomidate.
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maintains the electroencephalographic burst suppression
ratio at 80% (in a background of 1% isoflurane) and (b) it
administers a steady-state dose that is 1.3 times that
required to produce immobility to a standard noxious sti-
mulus (in the absence of isoflurane). The total doses of
CPMM and etomidate delivered during 2-hour infusions
were 143 and 36 mg/kg, respectively. During hypnotic
infusion, the body temperature of each rat was measured
with a rectal thermistor and maintained at 37 ± 0.2°C by
using a heat lamp. Rats in the control group received dex-
amethasone but no hypnotic during the hypnotic infusion
protocol and were allowed to roam freely in their cages.
Assessment of adrenocortical function during hypnotic
drug infusion
Rats were given intravenous dexamethasone (0.2 mg) to
suppress corticosterone synthesis elicited by endogenous
ACTH and reduce baseline corticosterone concentrations.
Rats were then randomly assigned to CPMM, etomidate,
or control groups. Two hours after dexamethasone admin-
istration, a baseline blood sample was drawn, a second
dose of dexamethasone was given, and the hypnotic infu-
sion protocol was begun. Ninety minutes after the proto-
col began, ACTH (0.25 mg/kg) was given intravenously to
stimulate corticosterone production, and a second blood
sample was drawn 30 minutes later (that is, at the end of
the infusion protocol). Thus, the corticosterone concen-
tration in the second blood sample was a measure of
the extent of adrenocortical inhibition during the final
30 minutes of the infusion (Figure 2A).
Assessment of adrenocortical recovery after hypnotic
drug infusion
Rats were given intravenous dexamethasone (0.2 mg) and
randomly assigned to CPMM, etomidate, or control
groups. Two hours after dexamethasone administration, a
baseline blood sample was drawn, a second dose of dexa-
methasone was given, and the hypnotic infusion protocol
was begun. After the 120-minute infusion protocol was
completed, ACTH (0.25 mg/kg) was given intravenously
every 30 minutes for 3 hours to maintain adrenocortical
stimulation, and blood samples were drawn 30 minutes
after each ACTH dose. The time course of adrenocortical
recovery was assessed from the time-dependent corticos-
terone concentration increase that occurred with repetitive
ACTH administration (Figure 2B).
Measurement of serum corticosterone concentrations
Serum corticosterone concentrations in blood samples
were determined as previously described [11] by using an
enzyme-linked immunosorbent assay (Diagnostic Systems
Laboratories, Webster, TX, USA) and a 96-well plate
reader (Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
All data are presented as mean ± standard deviation. Sta-
tistical analyses were carried out by using Prism version
5.0 for the Macintosh (GraphPad Software, Inc., La Jolla,
CA, USA). For multiple comparisons, we performed
either a one-way or two-way analysis of variance followed
by a Bonferroni post-test. A P value less than 0.05 was
considered statistically significant.
Results
Suppression of adrenocortical function during hypnotic
drug infusion
Baseline serum corticosterone concentrations prior to the
start of the infusion protocol were not significantly differ-
ent among the three groups and averaged 37 ± 111 ng/mL.
After administration of ACTH, serum corticosterone
concentrations in the CPMM and etomidate groups were
100 ± 64 ng/mL (n = 6) and 33 ± 32 ng/mL (n = 6),
respectively (Figure 3). These values were not significantly
different from one another but were significantly lower
than that measured in the control group (615 ± 265
ng/mL, n = 6, P < 0.001).
Recovery of adrenocortical function after hypnotic drug
infusion
Baseline serum corticosterone concentrations prior to
the start of the infusion protocol or administration of
ACTH were not significantly different among the three
groups and averaged 63 ± 108 ng/mL. With ACTH
administration, serum corticosterone concentrations
increased over time in all three groups (Figure 4). At
every time point of the study, ACTH-stimulated serum
corticosterone concentrations in the CPMM and control
groups were not significantly different. In contrast,
ACTH-stimulated serum corticosterone concentrations
in the etomidate group were significantly lower than in
either the CPMM or control groups for all time points.
Discussion
This study shows that, during 120-minute continuous
infusions of CPMM and etomidate, ACTH-stimulated
serum corticosterone concentrations were significantly
reduced relative to the control value. However, after the
infusion was completed, ACTH-stimulated serum corti-
costerone concentrations were not significantly different
from control values within 30 minutes in rats that
received CPMM, but remained significantly lower than
control values for more than 3 hours in rats that
received etomidate. We conclude that continuous infu-
sions of CPMM and etomidate cause adrenocortical
suppression but that adrenocortical recovery occurs
more quickly after infusions of CPMM as compared
with etomidate.
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Suppression of adrenocortical function is a common
side effect of etomidate administration that results from
the inhibition of 11b-hydroxylase, an enzyme required for
the biosynthesis of cortisol, corticosterone, and aldoster-
one [4,16-18]. This potentially deadly side effect has led
anesthesiologists and intensivists to abandon its use by
continuous infusion for anesthetic maintenance or seda-
tion [3,19]. Although etomidate continues to be used as an
anesthetic induction agent, significant concerns about the
impact of even a single bolus dose remain because even
this brief exposure produces long-lasting adrenocortical
suppression that may be detrimental to the critically ill
[6-10,20-22].
Why is adrenocortical function suppressed for so long
after etomidate administration? The adrenocortical inhi-
bitory potency of etomidate is two to three orders of
magnitude greater than its hypnotic potency [23-27].
Thus, a typical anesthetic induction dose of etomidate
represents a massive overdose with respect to adrenocor-
tical inhibition, and etomidate concentrations in blood
fall below those that produce adrenocortical suppression
only after the passage of multiple elimination half-lives.
Our goal in creating soft etomidate analogues was to
produce agents that may be given as either a bolus (for
anesthetic induction) or continuous infusion (for anes-
thetic maintenance) without producing persistent adreno-
cortical suppression since they are rapidly eliminated. We
hoped that such agents might also allow fast emergence
from anesthesia, which might ultimately benefit patients
while improving operational efficiencies. Our first soft eto-
midate analogue, methoxycarbonyl etomidate, achieved
these goals when given as a single bolus since hypnotic
recovery was rapid and adrenocortical suppression was
brief [11]. However, because it was so rapidly metabolized
and possessed relatively low hypnotic potency, dosing
Figure 2 Schematic diagrams depicting the protocols used for
assessing adrenocortical function (a) during or (b) after
hypnotic infusion. (a) A baseline blood sample was drawn and the
hypnotic infusion was begun. Ninety minutes after beginning the
infusion, adrenocorticotropic hormone (ACTH) was administered
and a second blood sample was drawn at the end of the infusion
30 minutes later. (b) A baseline blood sample was drawn and the
hypnotic infusion was begun. Upon completion of the 120-minute
hypnotic infusion, ACTH dose was repetitively administered and a
blood sample was drawn every 30 minutes. For clarity,
dexamethasone administration is not shown.
Figure 3 Adrenocorticotropic hormone-stimulated serum
corticosterone concentrations during 120-minute infusions.
Serum corticosterone concentrations in the cyclopropyl-
methoxycarbonyl etomidate (CPMM) and etomidate groups were
100 ± 64 ng/mL and 33 ± 32 ng/mL, respectively, versus 615 ± 265
ng/mL in the control group. *P < 0.001. Rats in the control group
received neither CPMM nor etomidate during the hypnotic infusion
period. Six rats were used in each group. NS, not significant.
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requirements during continuous infusion were extremely
high [13]. As a consequence, metabolite accumulated dur-
ing infusions and recovery times were highly dependent
upon the duration of hypnotic infusion (that is, recovery
was context-dependent).
With the goals of slowing methoxycarbonyl etomidate’s
exceptionally fast rate of metabolism and reducing the
extent of metabolite accumulation during infusions, we
modified the drug’s chemical structure by adding a cyclo-
propyl group directly adjacent to the metabolically labile
ester moiety (to sterically hinder enzymatic attack) and
shortening the spacer between that ester and the etomi-
date core (Figure 1). This structural change increased
both the duration of hypnotic action and hypnotic
potency by approximately eightfold [14]. As a result, dos-
ing requirements for continuous CPMM infusions are
one to two orders of magnitude lower than those for
methoxycarbonyl etomidate infusions, and neither hyp-
notic nor encephalographic recoveries are delayed by the
accumulation of metabolite [14,15].
We believe that the introduction of CPMM into clinical
practice could have a significant impact on patient care by
allowing anesthesia to be maintained, even in older or cri-
tically ill patients, without producing significant cardiovas-
cular depression or persistent adrenocortical dysfunction.
It may also allow more rapid and predictable anesthetic
emergence than is possible with currently available agents.
There are several limitations of our study. First is the
use of a rat model to study adrenocortical recovery after
hypnotic infusion. Rats often metabolize ester-containing
drugs (including etomidate) faster than humans [28,29].
Therefore, adrenocortical recovery following infusion of
CPMM and etomidate may be somewhat slower in
humans than we observed in rats. Second, rats use corti-
costerone, rather than cortisol, as the primary stress ster-
oid. Thus, we are studying a different steroid. However,
because the biosynthesis of both steroids requires 11b-
hydroxylase, suppression of corticosterone synthesis in
rats is expected to be a relevant measure of adrenocorti-
cal function in the setting of etomidate or CPMM admin-
istration. Finally, we used a protocol for assessing the
time course of adrenocortical recovery in which ACTH is
administered multiple times, introducing the potential
for adrenal fatigue toward the end of the study. Such fati-
gue would be greater for rats in the control and CPMM
groups that are most actively producing steroids but
would not alter our conclusions.
The development of soft etomidate analogues follows a
trend in drug development toward agents that are ultra-
short-acting and is in response to the need in the operating
room and intensive care unit for more precise temporal
control of drug effects [30]. Esmolol and remifentanil are
commonly used examples of soft drugs that serve this need
and use the same labile ester strategy employed in our eto-
midate analogues [31]. The esterase-metabolized soft cal-
cium channel blocker clevidipine was recently introduced
into clinical practice for the acute treatment of hyperten-
sion [32], and the esterase-metabolized soft midazolam
analogue remimazolam is currently undergoing clinical
trials [33]. By offering rapid emergence from anesthesia
and prompt return of adrenocortical function, CPMM may
join the growing list of soft drugs available for clinical use.
Conclusions
Adrenocortical function was suppressed during 120-min-
ute continuous infusions of CPMM and etomidate in a rat
model. However, after infusion termination, adrenocortical
recovery occurred in less than 30 minutes with CPMM
but persisted for more than 3 hours with etomidate.
Key messages
• Cyclopropyl-methoxycarbonyl etomidate (CPMM)
is a rapidly metabolized analogue of etomidate.
• CPMM and etomidate suppress adrenocortical ster-
oid synthesis during 120-minute continuous infusions.
• Upon termination of 120-minute continuous infu-
sions, adrenocortical recovery occurs faster with
CPMM (< 30 minutes) than with etomidate (> 3 hours).
Figure 4 Adrenocorticotropic hormone (ACTH)-stimulated
serum corticosterone concentrations following 120-minute
infusions. The baseline blood sample was drawn immediately prior
to beginning the hypnotic infusion and before administering ACTH.
ACTH was first administered at time 0 and then repetitively
administered every 30 minutes. Serum corticosterone concentrations
were measured in blood drawn 30 minutes after each ACTH dose.
The indicated times are when blood was drawn *P < 0.05 versus
control group. #P < 0.05 versus cyclopropyl-methoxycarbonyl
etomidate (CPMM) group. Six rats were used in each group.
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• CPMM may be a viable alternative to other sedative
hypnotics (for example, propofol, etomidate, and
inhaled agents) in which intraoperative hemodynamic
stability and rapid anesthetic recovery are desirable,
and adrenocortical suppression persisting for little
more than the duration of hypnotic administration is
acceptable.
Abbreviations
ACTH: adrenocorticotropic hormone; CPMM: cyclopropyl-methoxycarbonyl
etomidate.
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